Human Placentas and the Changing Face of Reproductive Toxicology Testing
Journal Title: Gynecology and Obstetrics Research – Open Journal - Year 2015, Vol 2, Issue 3
Abstract
Pharmaceuticals are in use by 40-98% of pregnant mothers in the developed world, varying by country. There is a significant potential for obstetricians to further maintain medical prescriptions for chronic diseases during pregnancy, provided there is confidence within the pharmaceutical industry on the safety of their products. The safety of medicinal products incurs several socioeconomic challenges, and the protection of maternal and fetal health is a foremost and top priority. Current guidelines for reproductive toxicity testing in rats and rabbits provide the required data for international regulatory bodies, such as the Federal Drug Agency (FDA) and the European Medicines Agency (EMA) and are described by the Organization for Economic Cooperation and Development (OECD). These animal studies include fetal organ anthropometry, but are devoid of much fetal organ functional data, so there is a case for improving animal data quality during reproductive toxicity testing. Human placental models have a real potential to refine, or even replace some animal use in the pharmaceutical industry, by predicting the probability of unfavourable events for fetal growth and development and highlighting additional specific outcome measures to be used in rat and rabbit reproductive toxicology testing.
Authors and Affiliations
Paul Brownbill
Keywords
Related Articles
- EP ID EP553558
- DOI 10.17140/GOROJ-2-e004
- Views 173
- Downloads 0
Etiology of Infection, Femoral Nerve and Splenic Injury by Abdominal Retractor
The aim of this work is to identify the underlying factors of infections in surgical wounds, as well as injury to the femoral nerve and spleen. Medical literature dating between the years 2000 and 2013 was reviewed using...
The Use of Localised Vaginal Drug Delivery as Part of a Neoadjuvant Chemotherapy Strategy in the Treatment of Cervical Cancer
Cervical cancer is the third most prevalent cancer in women globally, with 529,000 diagnosis and 275,000 deaths each year. It is especially prevalent in developing countries where approximately 85% of cases arise due to...
Low-Grade Serous Carcinoma – The Clinical Challenge
Low-grade serous carcinoma is one of the five major histological types of ovarian carcinoma associated with a specific biology. We reviewed three cases from our institution to demonstrate the variable clinical course and...
Tumor Conditioning Regimens: An Evolution in Cancer Treatment that Relies on Short-Term Sacrifice for Long-Term Gain
In this commentary, the authors discuss a new concept for tumor treatment, which is based on observations from published studies and clinical practice protocols. This new treatment regimen, which we coin “Tumor Condition...
Developmental Exposure to Endocrine Disrupting Chemicals Alters the Epigenome: Identification of Reprogrammed Targets
Endocrine disruptions induced by environmental toxicants have placed an immense burden on society to properly diagnose, treat and attempt to alleviate symptoms and disease. Environmental exposures during critical periods...